Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...

An international group of cancer experts has called for fundamental change to healthcare approaches for bile duct cancer, which kills three-quarters of patients within a year of diagnosis.

Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...

According to a new study published in the journal Pharmaceuticals, numerous compounds derived from cannabis may help disrupt multiple biological pathways involved in the progression of skin cancer.

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

Specifically, the CHMP has backed conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for children ...

Telefonica has introduced Quantum Telco at Mobile World Congress 2026, presenting a comprehensive portfolio of quantum technology solutions ...

Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

US FDA grants full approval to Pfizer’s Braftovi combination regimen in first-line metastatic colorectal cancer: New York Thursday, February 26, 2026, 12:00 Hrs [IST] Pfizer Inc ...

Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...